Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Combination index values for ReoT3D-chemotherapeutic combination regimens in NSCLC cells

From: Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

    Combination Index Values§   Combination Index Values§
Drugs & Cell Lines Drug Sensitivity IC50 (μM) Ratio* I ED50 ED75 ED90 Mean Ratio* II ED50 ED75 ED90 Mean
Paclitaxel            
   NCI-H460 0.003 ± 0.001 1:53 0.903 0.221 0.057 0.394 1:533 0.193 0.042 0.013 0.083
   HOP-92 38.50 ± 16.01 1:20 0.144 0.295 0.613 0.351 1:200 0.178 0.420 0.994 0.530
   NCI-H23 0.08 ± 0.04 1:20 0.577 0.303 0.159 0.347 1:200 0.329 0.061 0.011 0.134
   EKVX 56.06 ± 15.87 1:20 0.294 0.440 0.660 0.464 1:200 0.124 0.216 0.374 0.238
   NCI-H226 77.79 ± 25.08 1:20 0.543 0.344 0.218 0.368 1:200 0.004 1.30E-04 4.73E-06 0.001
   NCI-H322M > 100 1:20 0.069 0.092 0.133 0.098 1:200 0.078 0.081 0.084 0.081
Cisplatin            
   NCI-H460 5.31 ± 1.21 1:53 0.875 0.313 0.112 0.433 1:533 0.661 0.292 0.129 0.361
   HOP-92 6.82 ± 3.22 1:20 0.352 0.325 0.500 0.392 1:200 0.053 0.080 0.195 0.109
   NCI-H23 3.51 ± 1.15 1:20 0.579 0.487 0.530 0.532 1:200 0.546 0.248 0.342 0.379
   EKVX 29.34 ± 6.62 1:20 0.955 0.559 0.328 0.614 1:200 0.933 0.754 0.610 0.766
   NCI-H226 14.71 ± 6.60 1:20 0.615 0.297 0.145 0.352 1:200 0.558 0.081 0.013 0.217
   NCI-H322M > 100 1:20 > 10 > 10 > 10 > 10 1:200 > 10 > 10 > 10 > 10
Gemcitabine            
   NCI-H460 0.01 ± 0.003 1:53 0.199 0.126 0.126 0.150 1:533 0.006 0.017 0.054 0.025
   HOP-92 0.83 ± 0.61 1:20 0.372 0.117 0.047 0.179 1:200 0.099 0.110 0.127 0.112
   NCI-H23 0.02 ± 0.01 1:20 0.630 0.249 0.285 0.388 1:200 0.207 0.092 0.369 0.223
   EKVX > 100 1:20 > 10 > 10 > 10 > 10 1:200 > 10 > 10 > 10 > 10
   NCI-H226 17.69 ± 10.16 1:20 0.112 0.030 0.008 0.050 1:200 0.057 0.007 0.001 0.021
   NCI-H322M > 100 1:20 > 10 > 10 > 10 > 10 1:200 > 10 > 10 > 10 > 10
Vinblastine            
   NCI-H460 0.92 ± 0.35 (nM) 1:5.3 0.255 0.149 0.089 0.164 1:53.3 0.069 0.045 0.031 0.049
   HOP-92 48.80 ± 23.08 1:20 1.749 7.049 > 10 > 10 1:200 0.133 1.256 11.922 4.437
   NCI-H23 1.49 ± 1.09 (nM) 1:2 0.316 0.056 0.019 0.130 1:20 0.367 0.052 0.008 0.142
   EKVX > 100 1:20 3.275 1.927 1.134 2.112 1:200 0.193 0.651 2.192 1.012
   NCI-H226 28.46 ± 14.13 1:20 0.081 0.043 0.023 0.049 1:200 0.027 0.006 0.001 0.012
   NCI-H322M > 100 1:20 > 10 > 10 > 10 > 10 1:200 > 10 > 10 > 10 > 10
  1. Sensitivities of 6 NSCLC cell lines to each listed drug tested as a single agent (mean ± SD from 3 separate experiments). *Constant ratios of drug concentrations in μM (or nM) and ReoT3D MOI doses in plaque forming units per cell used for combination studies (see text). §Combination index (CI) values shown are from representative experiments repeated three times with similar results. Abbreviations: ReoT3D, reovirus type 3 Dearing; NSCLC, non-small cell lung cancer; IC50, 50% inhibitory concentration; MOI, multiplicity of infection expressed in plaque forming units per cell.